Resolution: standard / high
Figure 1.
Clinical trials evaluating combinations of trastuzumab and other signal transduction
inhibitors targeting erbB growth factor receptor tyrosine kinases (for example OSI-774,
ZD-1839, GW572016, CI-1033) or downstream kinases (R115,777, BAY 43-9006, CI-1040)
are needed to enhance the anticancer activity of trastuzumab and reverse trastuzumab
resistance in HER2-positive disease. Erk, extracellular signal-regulated protein kinase;
MEKK, MAP kinase/Erk kinase kinase; PI3-kinase, phosphoinositide 3-kinase.
de Bono et al. Breast Cancer Res 2003 5:154 doi:10.1186/bcr597